Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference.
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Wednesday, December 1st, 2021 at 4:20 p.m. ET.
A live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available for at least two weeks following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences’s clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005311/en/